V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Bio-Techne Corporation Executive Compensation (FY25)

TECH · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Kim Kelderman
Latest say-on-pay support
=
October 30, 2025
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Bio-Techne Corporation brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): November 5, 2025
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Bio-Techne Corporation brief$1,500Get the executive brief
Velarion Member, one year
377 figures on this page: 367 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kim Kelderman: $6,852,495 → $8,151,181 (19.0% higher)
Say-on-pay support: 86.0% → 71.6% (14.4 points lower)
CEO pay ratio: 78.5:1 → 88.9:1 (13.2% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Bio-Techne Corporation's chief executive and what were they paid?
Kim Kelderman was paid $8,151,181 in total compensation as President and CEO for fiscal 2025. Compared with the $6,852,495 reported for fiscal 2024, Kelderman's total was 19.0% higher.
What was Bio-Techne Corporation's say-on-pay result?
Shareholders supported the say-on-pay proposal with 71.6% of votes cast including abstentions in favor at the meeting held October 30, 2025 for fiscal 2025.
Which companies are in Bio-Techne Corporation's peer group?
Companies named in the disclosed peer group include Align Technology, Inc., Alkermes plc, Avantor, Inc., Bio-Rad Laboratories, Inc. and EXACT Sciences Corporation, among others.
What is Bio-Techne Corporation's chief executive pay ratio?
The company reported a chief executive pay ratio of 88.9:1 for fiscal 2025, against median employee compensation of $91,707.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Charles Kummeth
Former Chief Executive Officer
◇—◇◇◇—◇◇
James Hippel
Executive Vice President – Finance and Chief Financial Officer
◇—◇◇◇—◇◇
Brenda Furlow
Former Executive Vice President and General Counsel
◇—◇◇◇—◇◇
Kim Kelderman
President, Diagnostics and Genomics
◇—◇◇◇—◇◇
William Geist
President – Protein Sciences
◇—◇◇◇——◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Charles Kummeth
Former Chief Executive Officer
◇—◇◇◇—◇◇
James Hippel
Executive Vice President – Finance and Chief Financial Officer
◇—◇◇◇—◇◇
Kim Kelderman
President, Diagnostics and Genomics
◇—◇◇◇—◇◇
William Geist
President – Protein Sciences
◇—◇◇——◇◇
Brenda Furlow
Former Executive Vice President and General Counsel
Departed during or after this year
◇—◇◇◇—◇◇
Shane Bohnen
Senior Vice President – General Counsel and Corporate Secretary
◇—◇◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kim Kelderman
President and CEO Former President, Diagnostics and Genomics
◇—◇◇◇—◇◇
Charles Kummeth
Former President and CEO
Departed during or after this year
◇—◇—◇—◇◇
James Hippel
Executive Vice President and CFO
◇—◇◇◇—◇◇
William Geist
President, Protein Sciences
◇—◇◇◇—◇◇
Matthew McManus
President, Diagnostics and Genomics
◇—◇◇◇—◇◇
Shane Bohnen
Senior Vice President and General Counsel
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kim Kelderman
President and CEO
◇—◇◇◇—◇◇
James Hippel
Executive Vice President and CFO
◇—◇◇◇—◇◇
William Geist
President, Protein Sciences
◇—◇◇◇—◇◇
Matthew McManus
President, Diagnostics and Spatial Biology
◇—◇◇◇—◇◇
Shane Bohnen
Senior Vice President and General Counsel
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
James HippelRSU◇——◇——◇
James HippelRSU◇——◇——◇
James HippelPSU◇◇◇—◇—◇
James HippelOPTION◇——◇—◇◇
Kim KeldermanRSU◇——◇——◇
Kim KeldermanPSU◇◇◇—◇—◇
Kim KeldermanOPTION◇——◇—◇◇
Matthew McManusPSU◇◇◇—◇—◇
Matthew McManusOPTION◇——◇—◇◇
Matthew McManusRSU◇——◇——◇
Shane BohnenPSU◇◇◇—◇—◇
Shane BohnenRSU◇——◇——◇
Shane BohnenOPTION◇——◇—◇◇
William GeistPSU◇◇◇—◇—◇
William GeistRSU◇——◇——◇
William GeistOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Matthew McManusOption◇—◇2/1/2031
PSU◇◇——
RSU◇◇——
Shane BohnenOption◇—◇4/3/2030
Option◇—◇8/15/2029
Option◇—◇8/5/2027
RSU◇◇——
RSU◇◇——
Option◇—◇8/6/2028
Option◇—◇8/15/2030
PSU◇◇——
William GeistOption◇—◇2/1/2029
Option◇—◇8/15/2029
PSU◇◇——
Option◇—◇8/15/2030
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Kim KeldermanOption◇—◇2/1/2031
Option◇—◇11/1/2030
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇8/5/2027
Option◇—◇8/15/2030
Option◇—◇8/15/2029
RSU◇◇——
Option◇—◇8/6/2028
PSU◇◇——
James HippelOption◇—◇8/6/2028
Option◇—◇8/15/2030
PSU◇◇——
PSU◇◇——
Option◇—◇8/5/2027
PSU◇◇——
RSU◇◇——
Option◇—◇8/15/2029
Charles KummethOption◇—◇8/6/2028
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇8/5/2027
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert V. Baumgartner
Board chair
◇◇◇——◇◇
John L. Higgins
◇◇◇——◇◇
Julie L. Bushman
◇◇◇——◇◇
Roeland Nusse, Ph.D
◇◇◇——◇◇
Alpna Seth, Ph.D
◇◇◇——◇◇
Rupert Vessey, MA, BM BCh, FRCP, DPhil
◇◇◇——◇◇
Joseph Keegan, Ph.D
◇◇◇——◇◇
Judith Klimovsky, M.D
◇◇◇——◇◇
Amy Herr, Ph.D
◇◇◇——◇◇
Randolph C Steer, M.D., Ph.D
◇————◇◇
Kim Kelderman served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as 50% stock options, 50% restricted stock.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Align Technology, Inc. ALGN
  • Alkermes plc ALKS
  • Avantor, Inc. AVTR
  • Bio-Rad Laboratories, Inc. BIO
  • EXACT Sciences Corporation EXAS
  • Globus Medical, Inc. GMED
  • Haemonetics Corporation HAE
  • Insulet Corporation PODD
  • Integra LifeSciences Holdings Corp IART
  • Masimo Corporation MASI
  • Natera, Inc. NTRA
  • Penumbra, Inc. PEN
  • QIAGEN N.V. QGEN
  • QuidelOrtho Corporation QDEL
  • Repligen Corporation RGEN
  • Revvity Inc. RVTY
  • Teleflex Inc. TFX
  • Waters Corp. WAT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025October 30, 2025=◇◇◇
2024October 25, 2024=◇◇◇
2023October 26, 2023=◇◇◇
2022October 27, 2022=◇◇◇
2021October 28, 2021=◇◇◇
2020November 2, 2020=◇◇◇
2019October 28, 2019=◇◇◇
2018October 26, 2018=◇◇◇
2017October 26, 2017=◇◇◇
2016October 28, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Bio-Techne Corporation files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Bio-Techne Corporation disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Bio-Techne Corporation sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Bio-Techne Corporation's disclosed peer group is defensible, who names Bio-Techne Corporation back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
377 figures on this page: 367 cited to the filing that reported them, 10 calculated from figures it prints.
367 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001104659-25-106631
  2. 0001308179-25-000599
    Director Compensation · Grants of Plan-Based Awards · Pay Ratio Disclosure
  3. 0001558370-24-013879
  4. 0001308179-24-000703
  5. 0001558370-23-017051
  6. 0001308179-23-000977
  7. 0001558370-22-015710
  8. 0001437749-21-024664
  9. 0001437749-20-022390
  10. 0001437749-19-020780
  11. 0001437749-18-018887
  12. 0001437749-17-017673
  13. 0001437749-16-040643
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bio-Techne Corporation executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/TECH (accessed 2026).
Short form: data: Velarion

The Bio-Techne Corporation brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bio-Techne Corporation and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Bio-Techne Corporation discloses

The companies named in TECH's own disclosed peer group.

Align Technology, Inc.Alkermes plcAvantor, Inc.Bio-Rad Laboratories, Inc.EXACT Sciences CorporationGlobus Medical, Inc.Haemonetics CorporationInsulet CorporationIntegra LifeSciences Holdings CorpMasimo CorporationNatera, Inc.Penumbra, Inc.QuidelOrtho CorporationRepligen CorporationRevvity Inc.Teleflex Inc.Waters Corp.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy